This week I’ve been attending the excellent AACR Special Conference on Tumour Immunology and Immunotherapy here in Miami Beach. I must say that it’s really rather nice to have a local event literally less than 20 blocks away for once – it sure beats all the stress and hassle of long distance travel!
Were any of the early IO developments flying high in Miami Beach this week?
The meeting is designed to “integrate multidisciplinary facets of basic cancer immunology and immunotherapy to broaden the understanding of ways to harness the immune system to treat cancer.”
In this latest conference report, we cover some key highlights and insights learned, as well as review some early clinical data that was presented on several fronts including new companies and novel approaches to CAR-T cell therapy, as well as an important update on STING agonism.
We also identify some emerging trends that may teach us more about the future landscape developments in immuno-oncology.
To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
Dr Michael Caligiuri (City of Hope)
In the first of our extended thought leader interviews relating to the latest mini-series, we explore NK cell research through the lens of one of the experts in this niche.
This one is more of a convivial fireside chat than the usual interviews where we discuss data, latest readouts, development blowouts, or clinical trials etc.
So who’s in the spotlight this time around?
It’s none other than Dr Michael Caligiuri (City of Hope) who also happens to be the current President of AACR.
What’s cool is that he has been involved in NK cell research for a couple of decades and has seen a lot of changes in that time. He’s also an engaging and humble researcher who had some interesting perspectives on where success in the future might lie with approaches in this niche.
So grab a cup of joe and settle down to learning an intriguing story…
To learn more from thought leaders and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.